MAAT INDEX

CLAIM #22880 · EMR (EMR) · 2025Q3 earnings call · Aug 6, 2025 · due Dec 31, 2025

North America, India and the Middle East and Africa have been strong. And we expect these regions to remain growth drivers with sustained investment across LNG, power and life sciences.

Lal Karsanbhai · CEO

PENDING
graded after results covering Dec 31, 2025 are reported

In context

company's first step in integrating test optimized AI technology into its trusted LabVIEW portfolio will aid engineers in unlocking the full potential of our world-class software tools to address the increasing complexity of test and measurement across industries like semiconductor, transportation and electronics. Nigel can analyze, code and provide recommendations for improvements when developing and executing tests through plain language prompts, enabling engineers to focus on their own innovation and business goals. Please turn to Slide 4. Investments in automation continue to drive resilient demand in Emerson's process and hybrid markets as customers seek to modernize and improve their operations. The discrete recovery progressed further, particularly in test and measurement markets. North America, India and the Middle East and Africa have been strong. And we expect these regions to remain growth drivers with sustained investment across LNG, power and life sciences. Our industrial software, ACV again grew double digits over the prior year and ended the quarter at $1.5 billion. Underlying orders grew 4% and led by Test & Measurement, up 16% and with our process and hybrid businesses again up mid-single digits. MRO remained strong at 62% of sales with software and cybersecurity upgrades driving increased activity in long-term service agreements. The dynamic tariff environment persisted and our exposure was less than expected in the quarter. As the quarter progressed, we decided to ease the scope of surcharges, which meaningfully impacted our third quarter sales growth. Underlying sales growth was 3%, and we delivered excellent profitability. Emerson's adjusted earnings per share of $1.52 met the top end of our guide and better-than-expected free cash f

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2025Q3 earnings call.